• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, April 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Scientists caution that a rare childhood liver cancer can spread to the brain

Bioengineer by Bioengineer
March 19, 2018
in Biology
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A surprising finding by Rockefeller University scientists about a rare liver cancer's behavior could lead to more comprehensive patient monitoring and hopefully better outcomes.

The scientists recommend that people with advanced-stage fibrolamellar hepatocellular carcinoma, which mostly affects teenagers and young adults, receive regular neuroimaging scans because of the tumor's apparent ability to metastasize to the brain. Solid tumors, including those in the liver, don't usually spread to the brain, so scans to monitor fibrolamellar patients' progress typically don't include the head.

Earlier detection of brain metastases could increase the chances of successful surgical removal of the tumors, says Sanford Simon, whose Laboratory of Cellular Biophysics previously identified the genetic driver behind fibrolamellar. It also could help clinicians to make more informed choices about what drugs to use.

Only a minority of fibrolamellar patients will develop brain metastases, Simon expects. Still, testing for that possibility is important when a tumor's spread can have such severe consequences. About 200 cases of fibrolamellar are reported worldwide each year, though Simon believes the disease is underdiagnosed. Only about one in three patients survive beyond five years.

In a paper published recently in the journal Pediatric Blood & Cancer, he and colleagues document three cases in which fibrolamellar patients, all 18-year-old women, were found to have developed brain tumors. Cranial scans were performed only after the patients developed symptoms including severe headaches and changes in mental status. The tumors had also metastasized to the lungs of the three patients, one of whom had died when the paper was published.

Metastasis is common with fibrolamellar, partly because the disease isn't usually detected until it is at an advanced stage. Early symptoms, such as abdominal pain, could have many causes, and doctors may first check adolescent patients for issues such as stress or lactose intolerance.

Simon suggests that clinicians perform an ultrasound when teens complain about abdominal pain over an extended period, at least to rule out cancer.

The finding that fibrolamellar can spread to the brain doesn't immediately add to scientists' understanding of the biology of the disease, Simon says, but is nevertheless significant as it may offer immediate ways to improve treatment. Meanwhile, his team is working to develop a cure for fibrolamellar that acts by directly targeting the genetic driver of the disease. In other investigations, they are seeking to identify biomarkers in the blood that could lead to earlier detection of fibrolamellar and better tracking of patients' progress after tumors are surgically removed.

Another way Simon and his colleagues are trying to help patients more immediately is through extensive testing of existing drug compounds that have already been assessed for human safety. This could yield more effective chemotherapies for fibrolamellar in the near future, he says.

###

Media Contact

Katherine Fenz
[email protected]
212-327-7913
@rockefelleruniv

http://www.rockefeller.edu

https://www.rockefeller.edu/news/21508-scientists-caution-rare-childhood-liver-cancer-can-spread-brain/

Related Journal Article

http://dx.doi.org/10.1002/pbc.26919

Share12Tweet7Share2ShareShareShare1

Related Posts

Peptidoglycan Patterns Guide Streptococcus pneumoniae Division

Peptidoglycan Patterns Guide Streptococcus pneumoniae Division

April 7, 2026
Protein Behind Cancer Cell Resistance to Treatment Uncovered

Protein Behind Cancer Cell Resistance to Treatment Uncovered

April 7, 2026

New Tool Developed to Predict CRRT Risk and Enhance Early AKI Management After Lung Transplantation

April 6, 2026

How Mitochondrial DNA Influences Your Health: What Science Reveals

April 6, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    Revolutionary AI Model Enhances Precision in Detecting Food Contamination

    97 shares
    Share 39 Tweet 24
  • Promising Outcomes from First Clinical Trials of Gene Regulation in Epilepsy

    51 shares
    Share 20 Tweet 13
  • Imagine a Social Media Feed That Challenges Your Views Instead of Reinforcing Them

    1009 shares
    Share 399 Tweet 249
  • Popular Anti-Aging Compound Linked to Damage in Corpus Callosum, Study Finds

    44 shares
    Share 18 Tweet 11

About

BIOENGINEER.ORG

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tsu-Jae Liu’s Editorial Explores the Impact of AI on Engineering Innovation

PHIP Inhibits NuRD to Boost SWI/SNF Cancer Growth

Targeted Therapy Boosts Immune Attack in Ovarian Cancer

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 78 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.